This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Sunifiram
An AMPAkine compound structurally related to piracetam but estimated to be over 1,000 times more potent - enhances long-term potentiation, AMPA receptor signalling, and memory formation at microgram doses.
Benefits
What is Sunifiram?
Sunifiram (DM-235) is a synthetic AMPAkine nootropic derived from the piperazine backbone, structurally related to piracetam but with dramatically greater potency. Developed at the University of Firenze in Italy, sunifiram enhances cognitive function at doses measured in milligrams rather than the grams required for classical racetams.
The compound was first described in 2000 by Bhunandass Ghelardini and colleagues, who demonstrated that sunifiram reversed amnesia induced by scopolamine in mice at doses as low as 0.001 mg/kg - making it roughly 1,000 times more potent than piracetam in this model. A 2013 study published in Psychopharmacology by Moriguchi et al. showed that sunifiram enhances long-term potentiation (LTP) in hippocampal slices through activation of CaMKII and PKC signalling cascades downstream of AMPA receptor stimulation. It also increases glycine binding to NMDA receptors, further facilitating excitatory neurotransmission critical for learning and memory. While human clinical trials are lacking, the animal data consistently shows potent pro-cognitive and anti-amnesic effects.
- AMPA receptor potentiation: Enhances AMPA receptor-mediated excitatory transmission, increasing the speed and strength of synaptic signalling critical for learning
- LTP enhancement: Facilitates long-term potentiation in hippocampal CA1 neurons via activation of CaMKII (calcium/calmodulin-dependent protein kinase II) and protein kinase C
- NMDA receptor modulation: Increases glycine binding at the NMDA receptor glycine site, facilitating NMDA-dependent synaptic plasticity
- Acetylcholine release: Stimulates acetylcholine release in the prefrontal cortex, supporting attention and working memory
- PKC alpha activation: Activates protein kinase C alpha, which phosphorylates AMPA receptor subunits to increase their surface expression and conductance
- Typical dosage: 5-10 mg taken 1-3 times daily
- Sublingual administration: Often taken sublingually for faster absorption and higher bioavailability
- Start low: Begin with 3-5 mg to assess individual response before increasing
- Cycling recommended: Due to potency and limited long-term safety data, cycling (e.g. 5 days on, 2 days off) is commonly practised
- Onset: Effects typically noticed within 30-60 minutes. Sublingual onset is faster (15-30 minutes)
- Limited human data: No published human clinical trials exist. All efficacy data comes from animal models. Use with caution
- High potency: Due to its extreme potency, precise dosing with a milligram scale is essential. Volumetric dosing in solution is recommended for accuracy
- Overstimulation risk: Excessive doses may cause headache, jaw tension, insomnia, or anxiety due to excessive excitatory signalling
- Not well studied long-term: The long-term safety profile is unknown. Use conservatively and consider cycling
- Not regulated: Sunifiram is not approved as a medicine or food supplement in most jurisdictions. Legal status varies by country
Natural Sources & Forms
- Powder: Available from research chemical and specialist nootropic vendors as a powder for precise dosing
- Capsules: Some vendors offer pre-dosed capsules, though these are less common due to the low doses required
- Solution: Volumetric solutions allow more precise measurement of small doses
Frequently Asked Questions
An AMPAkine compound structurally related to piracetam but estimated to be over 1,000 times more potent - enhances long-term potentiation, AMPA receptor signalling, and memory formation at microgram doses.
The key benefits of Sunifiram include: Cognitive Enhancement, Creativity, Energy, Focus, Memory, Motivation.
AMPA receptor potentiation: Enhances AMPA receptor-mediated excitatory transmission, increasing the speed and strength of synaptic signalling critical for learning LTP enhancement: Facilitates long-term potentiation in hippocampal CA1 neurons via activation of CaMKII (calcium/calmodulin-dependent protein kinase II) and protein kinase C NMDA receptor modulation: Increases glycine binding at the NMDA receptor glycine site, facilitating NMDA-dependent synaptic plasticity Acetylcholine release: Stimulates acetylcholine release in the prefrontal cortex, supporting attention and working memory PKC alpha activation: Activates protein kinase C alpha, which phosphorylates AMPA receptor subunits to increase their surface expression and conductance
Typical dosage: 5-10 mg taken 1-3 times daily Sublingual administration: Often taken sublingually for faster absorption and higher bioavailability Start low: Begin with 3-5 mg to assess individual response before increasing Cycling recommended: Due to potency and limited long-term safety data, cycling (e.g. 5 days on, 2 days off) is commonly practised Onset: Effects typically noticed within 30-60 minutes. Sublingual onset is faster (15-30 minutes)
Limited human data: No published human clinical trials exist. All efficacy data comes from animal models. Use with caution High potency: Due to its extreme potency, precise dosing with a milligram scale is essential. Volumetric dosing in solution is recommended for accuracy Overstimulation risk: Excessive doses may cause headache, jaw tension, insomnia, or anxiety due to excessive excitatory signalling Not well studied long-term: The long-term safety profile is unknown. Use conservatively and consider cycling Not regulated: Sunifiram is not approved as a medicine or food supplement in most jurisdictions. Legal status varies by country
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!